Document is current
Any future updates will be listed below
-
Authors
Fernández-Garnacho, Elena María
Martínez-Muñoz, Cristina
Nadeu, Ferran
Clot, Guillem
Valero, Juan García
Araujo-Ayala, Ferran
Martínez-Farran, Ares
De Bolòs, Anna
Colomer, Dolors
Mozas, Pablo
Rivero, Andrea
Giné, Eva
López-Guillermo, Armando
Salaverria, Itziar
López, Cristina
Beà, Sílvia
Amador, Virginia
Demajo, Santiago
Jares, Pedro
Martín-Subero, José Ignacio
Pérez-Galán, Patricia
Campo, Elías
Hernández, Lluís
-
Funding
Funding for this research was provided by:
Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR 2018 FIB00696, Generalitat de Catalunya and FSE (European Union))
Agència de Gestió d'Ajuts Universitaris i de Recerca (Suport Grups de Recerca AGAUR ( 2021-SGR-01343))
Agència de Gestió d'Ajuts Universitaris i de Recerca (Suport Grups de Recerca AGAUR (2021-SGR-01294))
Agència de Gestió d'Ajuts Universitaris i de Recerca (Suport Grups de Recerca AGAUR (2021-SGR-01172))
Institució Catalana de Recerca i Estudis Avançats (Academia Researcher of the "Institució Catalana de Recerca i Estudis Avançats" (ICREA) of the Generalitat de Catalunya)
Ministerio de Ciencia e Innovación (Spanish Ministry of Science, Innovation and Universities (MCIN) & European Regional Development Fund (ERDF, “A way of making Europe”) PID2021-124894OB-I00)
Ministerio de Ciencia e Innovación (Spanish Ministry of Science, Innovation and Universities (MCIN) & European Regional Development Fund (ERDF, “A way of making Europe”) PID2021-123054OB-I00)
Fundació la Marató de TV3 ((“projecte finançat per Fundació La Marató de TV3”) TAIFOL project, 201933-30)
Fundació la Marató de TV3 ((“projecte finançat per Fundació La Marató de TV3”) 201920-30)
Interreg (POCTEFA program (IMLINFO EFA281/16 and THERAVLINFO EFA123/1)
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC (ONCG09/2025))
- License Information
-
More Information
Article History
Received: 12 June 2025
Accepted: 2 February 2026
First Online: 7 February 2026
Declarations
:
: E.C. has been a consultant for Takeda, NanoString, AbbVie and Illumina; has received honoraria from Janssen, EUSPharma and Roche for speaking at educational activities and research funding from AstraZeneca and is an inventor on 2 patents filed by the National Institutes of Health, National Cancer Institute: “Methods for selecting and treating lymphoma types,” licensed to NanoString Technologies, and “Evaluation of mantle cell lymphoma and methods related thereof”, not related to this project. F.N. has received honoraria from AbbVie, AstraZeneca, Janssen, and Sophia Genetics for speaking at educational activities. F.N. and E.C. have licensed to Diagnostica Longwood and Sophia Genetics the IgCaller algorithm. D.C. has received honoraria from AbbVie, Sophia Genetics, Thermofisher and AstraZeneca for speaking at educational activities. The remaining authors declare no competing financial interests.
: The cryopreserved samples used for the functional studies were obtained from MCL patients were obtained from the Hematopathology collection of the Biobank of the Hospital Clínic de Barcelona-IDIBAPS (Spain), in accordance with Declaration of Helsinki and national regulations, including the approval of the Institutional Review Board of Hospital Clínic de Barcelona. All patients provided written informed consent.
